Invivyd

IVVD Lead: Approved 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-05

Catalyst timeline

VMS063 / VBY329 corporate update2H 2026VMS063 / VBY329 corporate update, 2H 2026, routine
VYD2311 toplineOct 2026VYD2311 topline, Oct 2026, thesis-defining
VYD2311 / PEMGARDA BLA filing2H 2026/1H 2027VYD2311 / PEMGARDA BLA filing, 2H 2026/1H 2027, notable
IVVD corporate listing updateJan 19, 2027IVVD corporate listing update, Jan 19, 2027, routine
PEMGARDA FDA decisionJun 29, 2027PEMGARDA FDA decision, Jun 29, 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

VBY329

Protein Target: RSV

Respiratory Syncytial Virus Preclinical

VYD2311

Protein Target: SARS-CoV-2 spike protein RBD, SARS-CoV-2

COVID-19 Phase 3 intramuscular NCT06523153

PEMGARDA

pemivibart

Protein Target: SARS-CoV-2 spike protein RBD, SARS-CoV-2, SARS-CoV-2 spike protein receptor binding domain

COVID-19 Approved intravenous NCT06039449

VMS063

Protein Target: Measles Fusion (F) protein

Measles Preclinical

Technology platforms

Adimab Platform · Adimab

Adimab antibody discovery and optimization platform transferred to Invivyd; includes B-cell cloning using Adimab's proprietary yeast cell lines, antibody optimization libraries, trade secrets, protocols and software; used for discovery, engineering and optimization of antiviral mAbs targeting coronaviruses and other infectious diseases

Biotech Distilled coverage (2)

2026-09-30 UPDATE: Invivyd (IVVD) - The Readout That Wasn’t 🔒 Paid
2026-09-22 Invivyd (IVVD) — Scientific Deep Dive for PEMGARDA, VYD2311, and the Antibody Pipeline 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.